MA55590A - Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations - Google Patents

Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations

Info

Publication number
MA55590A
MA55590A MA055590A MA55590A MA55590A MA 55590 A MA55590 A MA 55590A MA 055590 A MA055590 A MA 055590A MA 55590 A MA55590 A MA 55590A MA 55590 A MA55590 A MA 55590A
Authority
MA
Morocco
Prior art keywords
il4i1
biomarker
interleukin
gene
induced
Prior art date
Application number
MA055590A
Other languages
English (en)
Inventor
Soumya Mohapatra
Christiane Opitz
Mirja Tamara Prentzell
Ahmed Sadik
Philipp Secker
Patterson Luis Felipe Somarribas
Saskia Trump
Original Assignee
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Helmholtz Zentrum Umweltforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Helmholtz Zentrum Umweltforsch filed Critical Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Publication of MA55590A publication Critical patent/MA55590A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA055590A 2019-04-10 2020-04-09 Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations MA55590A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19168304.4A EP3721894A1 (fr) 2019-04-10 2019-04-10 Gène 1 induit par l'interleukine-4 (il4i1) en tant que biomarqueur et ses utilisations

Publications (1)

Publication Number Publication Date
MA55590A true MA55590A (fr) 2022-02-16

Family

ID=66105002

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055590A MA55590A (fr) 2019-04-10 2020-04-09 Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations

Country Status (10)

Country Link
US (1) US20220170096A1 (fr)
EP (2) EP3721894A1 (fr)
JP (1) JP2022529423A (fr)
KR (1) KR20210151182A (fr)
CN (1) CN114126634A (fr)
AU (1) AU2020271634A1 (fr)
CA (1) CA3136524A1 (fr)
IL (1) IL286928A (fr)
MA (1) MA55590A (fr)
WO (1) WO2020208190A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4222167A1 (fr) 2020-09-30 2023-08-09 Nobell Foods, Inc. Protéines de lait recombinantes et compositions les comprenant
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
KR102465358B1 (ko) 2021-11-05 2022-11-11 주식회사 엑티브온 마그놀올, 호노키올, 또는 이의 조합을 포함하는 피부 외용제용 보존제 및 이를 포함하는 화장료 조성물
CN115044567B (zh) * 2022-04-07 2023-12-12 北京大学 一种肺癌的代谢免疫靶点il4i1及其应用
CN115785277B (zh) * 2022-09-09 2023-06-20 上海百英生物科技股份有限公司 一种抗IL4i1纳米抗体的制备及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066858A1 (fr) * 2008-12-10 2010-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement et de pronostic du cancer
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
US20170246259A1 (en) 2014-09-10 2017-08-31 Georgetown University Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1)
WO2017083809A1 (fr) 2015-11-13 2017-05-18 The Brigham And Women's Hospital, Inc. Ciblage de structures oxazole pour la thérapie contre les maladies inflammatoires
WO2017189353A1 (fr) * 2016-04-26 2017-11-02 Five Prime Therapeutics, Inc. Traitement de maladies respiratoires par ciblage de l'interleukine 4 induite par 1 (il4i1)
CA3025227A1 (fr) 2016-05-25 2017-11-30 Bayer Pharma Aktiengesellschaft 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
UY37466A (es) 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
JOP20190193A1 (ar) 2017-02-09 2019-08-08 Bayer Pharma AG ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
US11304946B2 (en) 2017-11-21 2022-04-19 Bayer Aktiengesellschaft 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists
EP3713923B1 (fr) 2017-11-21 2021-12-01 Bayer Aktiengesellschaft 2-phénylpyrimidine-4-carboxamides à utiliser en tant qu'inhibiteurs d'ahr
EP3713922A1 (fr) 2017-11-21 2020-09-30 Bayer Aktiengesellschaft 3-oxo-2,3-dihydropyridazine-4-carboxamides substitués par du soufre
EP3713931A1 (fr) 2017-11-21 2020-09-30 Bayer Aktiengesellschaft 3-oxo-6-hétéroaryl-2-phényl-2,3-dihydropyridazine-4-carboxamides
WO2019115586A1 (fr) 2017-12-12 2019-06-20 Phenex Discovery Verwaltungs-GmbH Oxalamides utilisés comme modulateurs de l'indoléamine 2,3-dioxygénase
EP3774755B1 (fr) 2018-03-29 2022-05-18 Phenex Discovery Verwaltungs-GmbH Composés spirocycliques utilisés comme modulateurs d'indoléamine 2,3-dioxygénase
WO2019206800A1 (fr) 2018-04-24 2019-10-31 Phenex Discovery Verwaltungs-GmbH Composés spirocycliques en tant que modulateurs de l'indoléamine 2,3-dioxygénase
WO2020021024A1 (fr) 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Composés bicycliques substitués en tant que modulateurs du récepteur d'hydrocarbures aryle (ahr)
SG11202101441SA (en) 2018-08-24 2021-03-30 Jaguahr Therapeutics Pte Ltd Tetrahydropyridopyrimidine derivatives as ahr modulators
WO2020043880A1 (fr) 2018-08-31 2020-03-05 Jaguahr Therapeutics Pte Ltd Composés hétérocycliques en tant que modulateurs de l'ahr

Also Published As

Publication number Publication date
WO2020208190A1 (fr) 2020-10-15
AU2020271634A1 (en) 2021-12-02
CA3136524A1 (fr) 2020-10-15
EP3721894A1 (fr) 2020-10-14
IL286928A (en) 2021-10-31
EP3952901A1 (fr) 2022-02-16
CN114126634A (zh) 2022-03-01
KR20210151182A (ko) 2021-12-13
US20220170096A1 (en) 2022-06-02
JP2022529423A (ja) 2022-06-22

Similar Documents

Publication Publication Date Title
MA55590A (fr) Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
MA50638A (fr) Biomarqueurs associés aux maladies médiées par l'interleukine-33 (il-33) et leurs utilisations
UA42295S (uk) Комп'ютер
AR086470A1 (es) Metodo implementado por un dispositivo de computacion y aparatos que utilizan tecnicas de canales de color y marcadores opticos
MA55080A (fr) Anticorps anti-mertk à affinité élevée et utilisations associées
BR112018010766A8 (pt) proteínas de ligação ao cd131 e usos das mesmas
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
UA42369S (uk) Комп'ютер
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
MA52190A (fr) Anticorps anti-trem-1 et utilisations associées
CO2022001021A2 (es) Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células
BR112017005430A2 (pt) um polímero orgânico curável que compreende pelo menos uma unidade de acilureia, sua preparação e uso.
CL2021001300A1 (es) Gen suicida
WO2018203864A3 (fr) Explosif primaire écologique
BR112021026508A2 (pt) Sílica precipitada e processo para sua fabricação
BR112021015481A2 (pt) Otimização biotecnológica de micro-organismos para a 1,2-desidrogenação de esteroides
EA202190228A1 (ru) Модификация связывающих молекул для минимизации уже существующих взаимодействий
TR201901321U5 (tr) eğitim seti
UA39904S (uk) Рекламний аркуш
TH167282A (th) แผ่นชีทเหล็กกล้าสำหรับกระป๋อง และวิธีการทำการผลิตของพวกมัน
TH174899A (th) ตัวหน่วงที่สามารถสับเปลี่ยนได้
JP1715570S (ja) 用箋挟
JP1715572S (ja) 用箋挟
JP1715568S (ja) 用箋挟